Tai, Yu-TzuLin, LiangXing, LijieCho, Shih-FengYu, TengtengAcharya, ChiragWen, KennethHsieh, Phillip A.Dulos, Johnvan Elsas, AndreaMunshi, NikhilRichardson, PaulAnderson, Kenneth2022-09-022019-02-01Tai, Yu-Tzu, Liang Lin, Lijie Xing, Shih-Feng Cho, Tengteng Yu, Chirag Acharya, Kenneth Wen et al. "APRIL Signaling via TACI Mediates Immunosuppression by T Regulatory Cells in Multiple Myeloma: Therapeutic Implications." Leukemia 33, no. 2 (2019): 426-438. DOI: 10.1038/s41375-018-0242-60887-69241476-5551https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37373140We here investigate how APRIL impacts immune regulatory T cells and directly contributes to the immunosuppressive multiple myeloma (MM) bone marrow (BM) microenvironment. First, APRIL receptor TACI expression is significantly higher in regulatory T cells (Tregs) than conventional T cells (Tcons) from the same patient, confirmed by upregulated Treg markers, i.e., Foxp3, CTLA-4. APRIL significantly stimulates proliferation and survival of Tregs, whereas neutralizing anti-APRIL monoclonal antibodies (mAbs) inhibit theses effects. Besides TACI-dependent induction of cell cycle progression and anti-apoptosis genes, APRIL specifically augments Foxp3, IL-10, TGFβ1, and PD-L1 in Tregs to further enhance Treg-inhibited Tcon proliferation. APRIL further increases MM cell-driven Treg (iTreg) via TACI-dependent proliferation associated with upregulated IL-10, TGFβ1, and CD15s in iTreg, which further inhibits Tcons. Osteoclasts producing APRIL and PD-L1 significantly block Tcon expansion by iTreg generation, which is overcome by combined treatment with anti-APRIL and -PD1/PD-L1 mAbs. Finally, APRIL increases IL-10-producing B regulatory cells (Bregs) via TACI on BM Bregs of MM patients. Taken together, these results define novel APRIL actions via TACI on Tregs and Bregs to promote MM cell survival, providing the rationale for targeting APRIL/TACI system to alleviate the immunosuppressive BM milieu and improve patient outcome in MM.en-USResearch Subject Categories::MEDICINE::Surgery::Anaesthetics and intensive care::AnaestheticsResearch Subject Categories::MEDICINE::Dermatology and venerology,clinical genetics, internal medicine::Internal medicine::HaematologyResearch Subject Categories::MEDICINE::Microbiology, immunology, infectious diseases::Immunology::Tumour immunologyJournal Article2018-08-0220182022-09-0210.1038/s41375-018-0242-6